News and Announcements
Endeavour Drinks Group (Operated by Woolworths Ltd) Signs Deal with OpenDNA (ASX:OPN) to Use AI Technology to Improve Customer Experience
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OpenDNA Limited (ASX: OPN) has recently announced the a signed customer agreement with Endeavour Drinks Group, a business element operated by Woolworths Limited.
KEY TAKEAWAYS:
- Agreement signed with Endeavour Drinks Group, a business which is operated by Woolworths Limited and which also is the owner of Dan Murphy’s, BWS and CellarMasters brands amongst others.
- OpenDNA and Endeavour have spoken to create and launch an app, which will provide users with the ability to choose “off the shelf” the best alcoholic beverage selection for their instantaneous needs.
- Through the app, consumers will be able to create a library of potential products tailored to their specific interests with also reflecting their preferences across a range of situations, moods and events.
- OpenDNA will create and power the app, generating revenue in the form of both app development and ongoing usage fee.
Speaking today in relation to the signing of the Agreement, OpenDNA CEO and MD Jay Shah said: “We are delighted to partner with a household name and trusted brand in the form of Endeavour Drinks Group to deliver to consumers an innovative and personalized app, which enables them to select the perfect accompaniment to any occasion. Through use of OpenDNA technology, not only will the app allow individual users to capture and catalogue their preferences for future reference, it will also enable them to access Endeavour’s extensive associated knowledge base to ensure that they receive the best and most personalised experience”.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
